Form 4: Vigil Neuroscience Director Vitorovic Receives Stock Option Award Repricing

Stefan Vitorovic, a director at Vigil Neuroscience, had stock option awards repriced on May 3, 2024, according to a Form 4 filing with the SEC.

Summary

• On May 3, 2024, Vigil Neuroscience director Stefan Vitorovic had existing stock option awards repriced.
• The repricing was approved by the Issuer's Board of Directors and became effective on the same day.
• The exercise price of one stock option award was adjusted to $3.03 per share, representing the fair market value of the Issuer's Common Stock on the effective date.
• The repriced stock option award will revert to its original exercise price if exercised during the Retention Period, which ends on the earliest of (i) the one-year anniversary of the Effective Date, (ii) a Sale Event, and (iii) the termination of the Reporting Person's Service Relationship by the Company other than for Cause or due to the Reporting Person's death or disability.
• Vitorovic now holds 12,155 shares from one stock option award and 13,928 shares from another stock option award.

Sentiment

Score: 6

Explanation: The document describes a routine stock option repricing, which is neither particularly positive nor negative. The sentiment is neutral.

Positives

• The stock option repricing aligns the director's incentives with the current market value of the company's stock.
• The retention period encourages the director to remain with the company.

Industry Context

Stock option repricing is a common practice to incentivize employees and executives, especially when a company's stock price has declined.

Stakeholder Impact

• The stock option repricing may incentivize the director to work towards increasing shareholder value.

Key Dates